CA2833705A1 — Use of dpp iv inhibitors
Assigned to Boehringer Ingelheim International GmbH · Expires 2007-11-15 · 19y expired
What this patent protects
The present invention relates to the use of a DPP IV inhibitor for the treatment of a patient suffering from heart failure, or for the treatment of a patient with transplanted islets of Langerhans or beta cells. The use may be combined with other active agents. Said uses can be e…
USPTO Abstract
The present invention relates to the use of a DPP IV inhibitor for the treatment of a patient suffering from heart failure, or for the treatment of a patient with transplanted islets of Langerhans or beta cells. The use may be combined with other active agents. Said uses can be employed for producing corresponding medicaments.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.